普洛药业：与安帝康生物签署CDMO项目战略合作框架协议

Core Viewpoint - The company has signed a strategic cooperation framework agreement with Jiaxing Andikang Biotechnology Co., Ltd. for the development and custom production of innovative drug raw materials and intermediates, establishing a long-term partnership for a duration of 10 years [1] Summary by Relevant Categories Agreement Details - The agreement is valid for 10 years, and it will terminate simultaneously with any project agreement that expires, is terminated, or is canceled [1] - The agreement does not involve substantial transactions and is not expected to have a significant impact on the company's operating performance for the current year [1] Future Implications - If the subsequent business progresses smoothly, it is expected to have a positive impact on future performance [1] - There is uncertainty regarding the achievement of specific cooperation and the fulfillment of the agreement [1] Historical Context - The company has successfully fulfilled all framework agreements signed in the past three years [1]